BPC-157
Stable gastric pentadecapeptide
A 15-amino-acid fragment of a gastric juice protein that has been studied unusually broadly in animal models. One of the most discussed research peptides, with an evidence base that is almost entirely preclinical.
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
At a glance
- 01
Stable in gastric juice
Unlike most peptides, BPC-157 stays intact in human gastric juice for hours. That property made it a model peptide for the question of how peptides can survive the digestive tract at all.
- 02
One molecule, many models
The literature spans tendon and muscle injury, gut mucosa, blood vessels and the nervous system, almost entirely in rat and mouse models. This breadth is rare and explains the sustained research interest.
- 03
Interaction with the NO system
A recurring finding is the interaction with the nitric oxide system and the cytoskeleton. Both are targets under intensive study in vascular and wound research.
Fields of research
- Tissue repair and wound healing
- Tendon, ligament, muscle
- Gastrointestinal mucosa
- Vascular biology and the NO system
- Neuroprotection
What it is
BPC-157 is a synthetic peptide of 15 amino acids. The sequence matches a segment of a protein found in human gastric juice, described in the 1990s at the University of Zagreb as “Body Protection Compound”. The peptide itself does not occur in nature in this form; it is a fragment.
The composition is striking: five prolines and four glycines in 15 positions, no aromatic amino acids, no cysteine, no methionine. That makes the molecule unusually resistant to oxidation and explains part of its stability.
What makes it special
Most peptides are degraded in the stomach within minutes. BPC-157 remains largely intact in human gastric juice for more than 24 hours. For peptide research that is interesting because it shows that sequence and structure alone, without chemical modification, can provide stability.
The second peculiarity is the breadth of models studied. Hardly any research peptide has been examined in so many different tissues. That is both the strength and the weakness of the literature: the findings are numerous, but they come predominantly from a single research group and have rarely been replicated independently.
What the studies say
The literature and patent review by Józwiak et al. (2025) summarises the state of play: in animal models, effects on wound healing, tendon and muscle injury, gut mucosa and blood vessels are described. The authors also stress that BPC-157 is not approved as a medicine by any authority and that robust human data are lacking.
Seiwerth et al. (2021) describe the findings specifically on wound healing in rodent models and discuss possible mechanisms via the NO system and angiogenesis. Again: these are animal studies.
State of evidence
Preclinical: extensive. Clinical: no controlled studies. Anyone researching BPC-157 is working on the question of whether and how the findings from animal models translate at all. That is exactly why it is a research peptide and not an active pharmaceutical ingredient.
Research status
BPC-157 is not approved as a medicine in any country. The World Anti-Doping Agency has listed it as prohibited since 2022 (category S0, non-approved substances). PURA LABS supplies BPC-157 for research use only, not for human or animal use.
Selected literature
- Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent reviewLiterature and patent review of the pentadecapeptide BPC 157. The data evaluated come predominantly from preclinical models; the authors stress the lack of clinical evidence.
- Stable gastric pentadecapeptide BPC 157 and wound healingReview of findings on BPC 157 in wound models (incisions, burns, diabetic ulcers) in rats and mice; mechanisms via the NO system and angiogenesis are discussed.